3D Biotechnologies

3D Bio Corp (3D Bio) is a clinical-stage regenerative medicine company that specializes in the development of living tissue implants using proprietary 3D bioprinting technology. The company's core platform, GMPrint, integrates advanced bio-ink chemistry, specialized 3D bioprinters, and proprietary cell expansion processes to create patient-specific, living tissue replacements. Their lead product, AuriNovo, is an autologous 3D-bioprinted ear implant currently in Phase 1/2a clinical trials for the treatment of microtia, a congenital ear deformity. In 2022, 3D Bio achieved a landmark medical milestone by performing the first-ever successful transplant of a 3D-bioprinted living tissue ear into a human patient. The company aims to expand its platform to address a wide range of medical needs, including orthopedic reconstruction, soft tissue repair, and eventually complex organ replacement.